REPL · Replimune Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $189.45M | $174.96M | $126.53M | $79.55M | $56.75M | $38.76M |
| SG&A | $72.18M | $59.81M | $50.55M | $38.77M | $23.20M | $17.44M |
| Total Operating Expenses | $261.63M | $234.77M | $177.08M | $118.31M | $79.95M | $56.20M |
| D&A | $3.50M | $2.65M | $2.45M | $2.15M | $1.71M | $533.0K |
| Operating Income | ($261.63M) | ($234.77M) | ($177.08M) | ($118.31M) | ($79.95M) | ($56.20M) |
| Interest Expense | $5.78M | $4.50M | $1.96M | $0 | $818.0K | $734.0K |
| Income Tax | $468.0K | $408.0K | $288.0K | $0 | $0 | $0 |
| Net Income | ($247.30M) | ($215.79M) | ($174.28M) | ($118.04M) | ($80.87M) | ($52.63M) |
| EPS - Basic | ($3.07) | ($3.24) | ($2.99) | ($1.75) | - | - |
| EPS - Diluted | ($3.07) | ($3.24) | ($2.99) | ($1.75) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $111.12M | $74.46M | $146.59M | $105.95M | $182.52M | $59.50M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $12.46M | $2.58M | $5.36M | $3.73M | $2.35M | $3.43M |
| Current Assets | $495.88M | $433.67M | $592.60M | $403.98M | $483.75M | $174.25M |
| Total Assets | $551.33M | $487.72M | $646.59M | $461.19M | $543.10M | $234.10M |
| Current Liabilities | $62.36M | $40.44M | $33.83M | $20.76M | $14.55M | $11.87M |
| Long-term Debt | $46.38M | $44.81M | $0 | - | - | $9.80M |
| Total Liabilities | $135.49M | $113.21M | $91.30M | $49.96M | $44.37M | $50.38M |
| Stockholders' Equity | $415.84M | $374.51M | $555.29M | $411.23M | $498.73M | $183.72M |
| Retained Earnings | ($948.58M) | ($701.28M) | ($485.49M) | ($311.20M) | ($193.17M) | ($112.30M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($192.25M) | ($185.47M) | ($128.05M) | ($82.18M) | ($61.39M) | ($60.55M) |
| Investing Cash Flow | ($23.80M) | $97.20M | ($142.50M) | ($1.81M) | ($188.78M) | ($5.23M) |
| Financing Cash Flow | $252.40M | $16.28M | $311.30M | $6.60M | $372.46M | $100.17M |
| CapEx | $6.69M | $5.66M | $2.27M | $2.34M | $2.39M | $6.54M |
| Free Cash Flow | ($198.94M) | ($191.13M) | ($130.32M) | ($84.52M) | ($63.78M) | ($67.09M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.80 | 0.89 | 0.75 | 0.72 | 0.79 | 1.27 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -44.9% | -44.2% | -27.0% | -25.6% | -14.9% | -22.5% |
| Return on equity | -59.5% | -57.6% | -31.4% | -28.7% | -16.2% | -28.6% |
| Return on invested capital | -44.7% | -44.2% | -25.2% | - | - | -22.9% |
| Liquidity | ||||||
| Current ratio | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 | 14.68 |
| Quick ratio | 7.95 | 10.72 | 17.52 | 19.46 | 33.25 | 14.68 |
| Cash ratio | 1.78 | 1.84 | 4.33 | 5.10 | 12.55 | 5.01 |
| Leverage | ||||||
| Debt / Equity | 0.11 | 0.12 | 0.00 | - | - | 0.05 |
| Debt / Assets | 0.08 | 0.09 | 0.00 | - | - | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -45.3x | -52.2x | -90.2x | - | -97.7x | -76.6x |
| Equity multiplier | 1.33 | 1.30 | 1.16 | 1.12 | 1.09 | 1.27 |
| Liabilities / Assets | 0.25 | 0.23 | 0.14 | 0.11 | 0.08 | 0.22 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.9x | 1.5x | 1.9x | 1.9x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.4% | -32.6% | -49.7% | -48.0% | - | - |
| Net income growth (YoY) | -14.6% | -23.8% | -47.7% | -46.0% | - | - |
| EPS growth (YoY) | 5.2% | -8.4% | -70.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -4.1% | -46.7% | -54.2% | -32.5% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 11.0% | -32.6% | 35.0% | -17.5% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Replimune Group against the 5 most active filers in the same SIC group.